Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

NCT00677326 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Difficulty in recruiting

Conditions

Breast Cancer

Interventions

BIOLOGICAL: VEGFR1 and VEGFR2

Sponsor

Tokyo University

Collaborators

[object Object]